Detalhe da pesquisa
1.
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer.
Clin Cancer Res
; 28(24): 5249-5253, 2022 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35925043
2.
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer.
Clin Cancer Res
; 23(23): 7165-7170, 2017 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28751443